Business & Economy · 22 views
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
On August 13, Ovid Therapeutics (NASDAQ: OVID ) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates.
Summary
On August 13, Ovid Therapeutics (NASDAQ: OVID ) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the update to lay out progress on two clinical programs, a leadership shakeup, and a deal that hands off one of its older assets in exchange for future payments. Cash on hand stood at $169.8 million, which the company says funds operations into 2029.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- I landed 4 job offers out of grad school and picked Meta. These 2 tactics helped me land my ideal offer.Continue reading
- We lived in an RV for 14 years before the Villa Vie Odyssey. The ship's shutdown hasn't changed how we want to live.Continue reading
- The United States Is Skipping COP31 in TurkeyContinue reading
- ‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow